Employment of Advanced Practice Clinicians in Physician Practices
Nurse practitioners (NPs) and physician assistants (PAs) are advanced practice clinicians that are increasingly involved in the delivery of health care services. The role of advanced practice clinicians in primary care has been described previously.
1-4 However, less is known about advanced practice clinicians in physician specialty practices. Results | In 2016, approximately 28% of all specialty practices employed advanced practice clinicians. Multispecialty practices were most likely (49%) and surgical specialties least likely (21%) to employ advanced practice clinicians. Among the top 10 specialties, advanced practice clinicians were employed in at least a quarter of practices in the following specialties: cardiology, obstetrics-gynecology, dermatology, gastroenterology, and orthopedic surgery. Specialty practices were more likely to employ NPs than PAs, with the exception of surgical practices, which relied more on PAs. Overall, from 2008 to 2016, there was a 22% increase in specialty practices employing advanced practice clinicians. As a point of comparison, there has been a 24% increase in advanced practice clinician use among primary care practices, such that 35% of these practices have at least 1 advanced practice clinician by 2016. Employment of NPs in specialty practices grew faster compared to PAs (33% vs 20% increase).
In the Figure we show that specialty practice advanced practice clinician employment was greatest in the Mountain West and West North Central regions (eg, North Dakota, South Dakota, Minnesota, and Iowa) during 2016-analogous to primary care. We also note that restricting our analyses to a balanced panel of practices from 2008 to 2016 did not meaningfully change the data patterns we observed.
Conclusions | We found that about 1 in 4 specialty practices employ advanced practice clinicians, compared with 1 in 3 primary care practices. Because the NP role was historically developed to focus on primary care and most advanced practice clinicians are NPs, one would expect that advanced practice clinicians would have a greater presence in primary care practices. The proportion of practices with advanced practice clinicians grew modestly over the past 8 years and the growth was similar across specialty and primary care practices. Overall growth in advanced practice clinicians may be driven by recent increases in graduates from advanced practice clinician programs, the emergence of value-based purchasing models that are incentivizing teambased care, and downward price pressure from public and private payers-making the lower costs of advanced practice clinician employment more attractive. Advanced practice clinicians may also be increasingly moving into specialty practices as specialist physicians embrace new roles for advanced practice clinicians.
6 These data have important limitations. They only include outpatient providers and they have no information about the specific duties of advanced practice clinicians in the practice. As the presence of advanced practice clinicians in the delivery of specialty care One concrete example of this problem occurs when a sponsor conducts several studies of a particular drug for a particular condition but only some (or none) of the studies make their way into the public domain, leaving a distorted body of public evidence. 3 Policies that require reporting to ClinicalTrials .gov are designed to ameliorate that problem. ClinicalTrials .gov currently has more than 255 000 registered studies, with summary results information for more than 28 000 studies, of which an estimated half lack corresponding publications. 2, 4, 5 To evaluate the influence of this resource on the evidence base, we examined the extent to which sets of trials registered in ClinicalTrials.gov by individual sponsors for the same drug and condition had results available publicly in ClinicalTrials.gov and/or PubMed.
Methods | We identified ClinicalTrials.gov-registered records for industry-sponsored, phase 2 to 4 trials of drugs or biologics, with at least 1 US study location, completed or terminated from January 1, 2007, through December 31, 2009 (allowing at least 7 years from trial completion for results reporting). We manually grouped trials into a sponsor-drug-condition trial set when the listed sponsor, drug, and condition appeared to be identical; we limited the analysis to a convenience sample of the first 96 sponsor-drug-condition trial sets identified. On July 25, 2017, we assessed the availability of results in PubMedcited publications and/or results posted in ClinicalTrials.gov based on methods used in prior research. 4 We also evaluated whether the drug was approved by the US Food and Drug Administration (FDA) for any use.
Results | Our sample consisted of 329 trials studying 86 drugs and representing 96 unique sponsor-drug-condition trial sets (eg, Amgen-sponsored trials of alendronate for osteoporosis). The median number of trials per set was 3 (range, 2-11).
The median proportion of trials in each set with results publicly available (in PubMed and/or ClinicalTrials.gov) was 100% (interquartile range, 62.5%-100%). Most trials used parallel assignment, double-blinding, randomization, and multiple sites and had more than 100 participants enrolled ( Discussion | ClinicalTrials.gov was a unique source of results for nearly one-quarter of sampled drug trials and more than onetenth of sampled sponsor-drug-condition trial sets. However, results remain unavailable in ClinicalTrials.gov or PubMed 7 or more years after study completion for nearly one-quarter of sampled drug trials and more than one-tenth of sampled sponsor-drug-condition trial sets. This study is limited by the convenience sampling approach, omission of unregistered
